Seres Therapeutics Q2 net income turns positive on VOWST sale gain

Seres Therapeutics

05/08/2026 12:19

Overview
US biotechnology firm's Q2 net income turned positive, driven by VOWST business sale gain
Operating expenses for Q2 fell yr/yr due to cost reduction efforts and lease terminations
Company reported positive topline data for SER-155 in immune checkpoint inhibitor-related enterocolitis

Outlook
Seres expects to fund operations through Q1 2027, excluding potential new partnerships or capital
Company is evaluating clinical development strategy for SER-155 in irEC and seeking partners
Seres continues to seek funding and partners to advance SER-155 and SER-603 programs

Result Drivers
PIPELINE PROGRESS - Positive topline data from SER-155 trial in irEC supported continued development and engagement with potential partners
COST REDUCTION - Lower research and development and general and administrative expenses due to reduced personnel, facilities costs, and other savings initiatives
LEASE TERMINATIONS - Early exit and restructuring of facility leases further reduced ongoing and future facility-related cash costs

Company press release: ID:nGNX4fbF9t

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$736,000
 
Q2 EPS
 
$0.47
 
Q2 Net Income
 
$4.58 mln
 
Q2 Operating Expenses
 
$22.009 mln
 
Q2 Operating Income
 
-$21.27 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Seres Therapeutics, Inc. is $17.00, about 223.8% above its August 4 closing price of $5.25

Reuters Recommended Reads
Aug 3 - Keros Therapeutics Q2 net loss narrows on lower expenses
Aug 4 - Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)